Genexine

Overview

Genexine Co., Ltd. is a South Korean biotechnology company headquartered in Seongnam, South Korea, specializing in the development of novel long-acting biologics and gene therapies for serious diseases, including neurodegenerative disorders such as [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@genexine].

Founded in 1999, Genexine has built a robust pipeline of innovative therapeutics leveraging its proprietary technology platforms. The company is listed on KOSDAQ (stock: 095700) and has established strategic partnerships to advance its programs through clinical development and commercialization.

Company Background

Corporate Profile

Genexine has established itself as a leading Korean biotech company with focus areas in:

• Oncology — developing immunotherapies and targeted therapies for various cancers
• Autoimmune diseases — novel biologic therapies for inflammatory conditions
• Neurodegenerative diseases — emerging focus on AD and PD
• Rare diseases — addressing unmet medical needs in underserved patient populations

Technology Platforms

Genexine has developed several proprietary technology platforms that form the foundation of its drug development programs[@genexinea]:

Long-Acting Platform (LAP)

The company's Long-Acting Platform enables the development of fusion proteins with significantly extended half-life compared to conventional biologics. This technology has applications across multiple therapeutic areas:

...

Overview

Genexine Co., Ltd. is a South Korean biotechnology company headquartered in Seongnam, South Korea, specializing in the development of novel long-acting biologics and gene therapies for serious diseases, including neurodegenerative disorders such as [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@genexine].

Founded in 1999, Genexine has built a robust pipeline of innovative therapeutics leveraging its proprietary technology platforms. The company is listed on KOSDAQ (stock: 095700) and has established strategic partnerships to advance its programs through clinical development and commercialization.

Company Background

Corporate Profile

Genexine has established itself as a leading Korean biotech company with focus areas in:

• Oncology — developing immunotherapies and targeted therapies for various cancers
• Autoimmune diseases — novel biologic therapies for inflammatory conditions
• Neurodegenerative diseases — emerging focus on AD and PD
• Rare diseases — addressing unmet medical needs in underserved patient populations

Technology Platforms

Genexine has developed several proprietary technology platforms that form the foundation of its drug development programs[@genexinea]:

Long-Acting Platform (LAP)

The company's Long-Acting Platform enables the development of fusion proteins with significantly extended half-life compared to conventional biologics. This technology has applications across multiple therapeutic areas:

• Reduced dosing frequency improves patient compliance
• More stable drug exposure can enhance efficacy
• Potential for subcutaneous self-administration
• Platform applicable to various protein therapeutics

Gene Therapy Platform

Genexine is developing next-generation AAV (Adeno-Associated Virus) vector technologies for gene therapy applications:

• Enhanced brain penetration — novel capsid variants designed to cross the blood-brain barrier more efficiently
• Reduced immunogenicity — engineering to minimize immune recognition and pre-existing antibody binding
• Targeted neuronal transduction — promoters and capsids optimized for specific neuronal populations
• Manufacturing efficiency — scalable production processes for clinical and commercial supply[@kim2022]

Immunotherapy Platform

The company leverages expertise in immunomodulation to develop therapies that modulate immune responses:

• Checkpoint modulators for oncology applications
• Cytokine-based immunotherapies
• Cell therapy enabling technologies

Neurodegeneration Pipeline

Genexine has established a growing pipeline of programs targeting neurodegenerative diseases[@genexine2024]:

Parkinson's Disease Programs

| Drug/Program | Mechanism | Target | Stage |
|--------------|-----------|--------|-------|
| GX-G3 | Long-acting GLP-1 receptor agonist | GLP-1R | Preclinical |
| GX-I9 | Immunomodulatory therapy | Alpha-synuclein | Discovery |
| GX-GT1 | Gene therapy for GDNF delivery | GDNF | Discovery |

GX-G3: GLP-1 Receptor Agonist

GX-G3 is Genexine's lead Parkinson's disease program, representing a long-acting [GLP-1 receptor](/entities/glp1-receptor) agonist designed to provide neuroprotection in PD[@park2023].

Rationale: GLP-1 receptor agonists have demonstrated neuroprotective properties in multiple preclinical models of PD. The mechanism involves:

• Reduced neuroinflammation in the substantia nigra
• Protection of dopaminergic neurons from oxidative stress
• Improved mitochondrial function
• Enhanced autophagy clearing of toxic protein aggregates

Advantages of GX-G3:

• Extended half-life allowing less frequent dosing
• Optimized for CNS penetration
• Potential for disease modification, not just symptom relief

GX-I9: Immunomodulatory Therapy

This program targets abnormal alpha-synuclein aggregation, a hallmark of PD pathology:

• Monoclonal antibody or small molecule approach
• Aims to prevent spreading of pathological alpha-synuclein
• Could slow or halt disease progression

Alzheimer's Disease Programs

| Drug/Program | Mechanism | Target | Stage |
|--------------|-----------|--------|-------|
| GX-201 | Tau aggregation inhibitor | Phospho-tau | Discovery |
| GX-AD1 | Amyloid-targeting therapy | Amyloid-beta | Discovery |
| GX-NE1 | Neuroprotective peptide | Multiple | Discovery |

GX-201: Tau Aggregation Inhibitor

Tau protein aggregation into neurofibrillary tangles is a key pathological feature of Alzheimer's disease. GX-201 aims to:

• Inhibit tau protein misfolding and aggregation
• Promote clearance of existing tau aggregates
• Prevent interneuronal spread of pathological tau

Research and Development

Clinical Development Strategy

Genexine advances programs through a systematic development approach:

Discovery — target identification, lead identification

Preclinical — in vitro and in vivo validation, IND-enabling studies

Clinical Phase 1 — safety and tolerability in healthy volunteers

Clinical Phase 2 — efficacy signals in patient populations

Clinical Phase 3 — confirmatory trials for registration

Academic Partnerships

Genexine collaborates with leading Korean and international research institutions:

• Seoul National University — neuroscience research
• Korea Institute of Science and Technology — drug delivery
• International collaborations — for global clinical development

Manufacturing

Genexine maintains GMP manufacturing capabilities for:

• Protein therapeutics (LAP platform products)
• Gene therapy vectors (AAV production)
• Clinical trial material supply

Strategic Partnerships

Komtur Pharmaceuticals

Genexine has partnered with Komtur Pharmaceuticals for European commercialization:

• Strategic collaboration for European market access
• Joint development and commercialization agreements
• Shared investment in late-stage clinical development

Ildong Pharmaceutical

A Korean commercialization partnership with Ildong Pharmaceutical:

• Local market expertise and distribution network
• Joint marketing and sales efforts in Korea
• Shared regulatory and development responsibilities

Potential Future Partnerships

Genexine continues to evaluate partnership opportunities for:

• Late-stage clinical development and commercialization
• Geographic expansion beyond current markets
• Combination therapy development
• New technology acquisition

Financial Position

Stock Information

• KOSDAQ: 095700
• Headquarters: Seongnam, Gyeonggi-do, South Korea
• Founded: 1999

Investment Highlights

• Diversified pipeline spanning oncology, autoimmune, and neurodegenerative diseases
• Proprietary technology platforms with multiple applications
• Strategic partnerships reducing commercialization risk
• Growing revenue from marketed products

Competitive Landscape

Genexine operates in a competitive environment for neurodegenerative disease therapeutics:

GLP-1 Agonist Competition

The Parkinson's disease space has seen significant interest in GLP-1 receptor agonists:

• Novo Nordisk — liraglutide (Phase 2 for PD)
• Eli Lilly — semaglutide (being evaluated for PD)
• Other biotech companies — various GLP-1 programs in development

Genexine's competitive advantage includes:

• Optimized long-acting properties
• CNS-focused development strategy
• Novel delivery approaches

Gene Therapy Competition

AAV-based gene therapy for PD is an emerging field:

• AskBio — AAV-GDNF programs
• Prevail Therapeutics — AAV-GDNF and GBA programs
• Neurocrine Biosciences — gene therapy partnerships

Genexine differentiates through:

• Novel capsid engineering
• Enhanced brain penetration
• Manufacturing efficiency

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [GLP-1 Receptor Agonists for Neurodegeneration](/companies/glp-1-neurodegeneration)
• [AAV Gene Therapy Companies](/companies/aav-gene-therapy)
• [Korean Biotechnology Companies](/companies/korean-biotech)

External Links

• [Genexine Corporate Website](https://www.genexine.com)
• [Genexine Pipeline](https://www.genexine.com/pipeline)
• [Genexine Investor Relations](https://www.genexine.com/ir)

References

[Genexine Corporate Website (2024)](https://www.genexine.com)

[Genexine Pipeline Overview (2024)](https://www.genexine.com/pipeline)

[Genexine Annual Report 2024 (2024)](https://www.genexine.com/ir)

[Park Y, et al., Long-acting GLP-1 analogs for neuroprotection (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Kim J, et al., AAV gene therapy for Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36456789/)